Key result
Injection of monoclonal antibodies against different epitopes on GPVI (JAQ2, JAQ3) induced depletion of GPVI with the same efficacy and kinetics as JAQ1 in vivo.
Why the study?
The mechanism by which monoclonal antibodies induce in vivo down-regulation of GPVI, specifically whether targeting the collagen-binding site is essential, was unclear.
Answers are grounded in this paper and cite their sources.
Anti-GPVI antibodies induce in vivo down-regulation of the GPVI receptor irrespective of their specific binding site or Fc involvement, suggesting a general mechanism for this potential antithrombotic strategy.
Glycoprotein (GP) VI is an essential collagen receptor on platelets and may serve as an attractive target for antithrombotic therapy. We have previously shown that a monoclonal antibody (mAb) against the major collagen-binding site on mouse GPVI (JAQ1) induces irreversible down-regulation of the receptor and, consequently, long-term antithrombotic protection in vivo. To determine whether this unique in vivo effect of JAQ1 is based on its interaction with the ligand-binding site on GPVI, we generated new mAbs against different epitopes on GPVI (JAQ2, JAQ3) and tested their in vitro and in vivo activity. We show that none of the mAbs inhibited platelet activation by collagen or the collagen-related peptide in vitro. Unexpectedly, however, injection of either antibody induced depletion of GPVI with the same efficacy and kinetics as JAQ1. Importantly, this effect was also seen with monovalent F(ab) fragments of JAQ2 and JAQ3, excluding the involvement of the Fc part or the dimeric form of anti-GPVI antibodies in this process. This indicates that anti-GPVI agents, irrespective of their binding site may generally induce down-regulation of the receptor in vivo.
No takes yet. Share an insight, caveat, or question.
Schulte et al. (2003) studied this question. Monoclonal antibodies against different epitopes on GPVI (JAQ2, JAQ3) vs. JAQ1 was evaluated on Depletion of GPVI in vivo. Injection of monoclonal antibodies against different epitopes on GPVI (JAQ2, JAQ3) induced depletion of GPVI with the same efficacy and kinetics as JAQ1 in vivo.
Synapse has enriched 10 related papers. Consider them for comparative context: